Dr. Willekens Presents Efficacy Findings for Reduced-Dose Venetoclax in AML
Christophe Willekens, MDAcute Myeloid Leukemia | July 16, 2024

Christophe Willekens, MD, describes his retrospective study comparing venetoclax dosing regimens in patients with AML presented at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain.

Advertisement
Advertisement

Advertisement
Advertisement
Editorial Board

Podcasts

Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | May 16, 2024
Dr. Hilal covers the debates surrounding MRD, whether he uses MRD to make treatment decisions, and more.
Listen Now
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse: MRD | April 26, 2024
Alan Skarbnik, MD, and Manni Mohyuddin, MBBS, discuss the concept of MRD in hematologic malignancies.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | April 10, 2024
HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | April 8, 2024
"Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 28, 2024
It's many different diseases, and it falls across many different specialties, according to the Dr. Goodman.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse: MRD | April 26, 2024
Elias Jabbour, MD, joined "The HemOnc Pulse" to discuss the function of MRD in treating ALL.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | July 17, 2024
Drs. Dahiya and Spiegel return for the second half of a discussion on reports of secondary T-cell malignancies after CAR-T.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 15, 2024
In episode four of the 2024 season, Dr. Coombs shares updates in CHIP from ASH 2023.

Video Insights

Knowledge Hubs

Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia

Trending on MashupMD

Network Websites